Quarterly report pursuant to Section 13 or 15(d)

SUPPLEMENTAL CASH FLOW INFORMATION (Details)

v3.8.0.1
SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Non-cash financial activities:    
Derivative liability issued $ 4,604
Preferred stock and warrants issued for fees 5
Net assets and liabilities recognized with the acquisition of Lewis and Clark Pharmaceuticals, Inc. 2,493
Accounts payable paid through issuance of debentures 70
Debentures issued to retire preferred stock 2,504
Debentures converted to common stock $ 38